Regentis Biomaterials Develops New Manufacturing Process For GelrinC, Off-The-Shelf Hydrogel Synchronized Erosion And Resorbable Implant For Treatment Of Painful Injuries To Focal Articular Knee Cartilage

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year

Proprietary process is already patented in several countries and is pending in the U.S.

HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use of organic solvents which are not only flammable and toxic but also take up a major portion of the manufacturing process volume. This new solvent-free process more than quadruples production yield per batch.